PitchSend

Investor Presentaiton

PRODUCTS DRIVING WW VOLUME GROWTH Contribution to 29% Q2 WW Volume Increase Growth Products New Products * All Other COVID-19 Antibodies -2.0% 5.6% 13.5% 12.1% *Includes $579 million from the sale of the worldwide rights for Baqsimi; Numbers may not add due to rounding New Products: Jaypirca, MounjaroⓇ, and OmvohⓇ Growth Products: CyramzaⓇ, EmgalityⓇ, Jardiance, Olumiant®, Retevmo®, TaltzⓇ, TrulicityⓇ, TyvytⓇ, and VerzenioⓇ COVID-19 Antibodies: bamlanivimab, etesevimab and bebtelovimab for the treatment of COVID-19 sold pursuant to Emergency Use Authorization or similar regulatory assumptions Not for promotional use 2023 Q2 EARNINGS Lilly 9

View entire presentation